NEOMYCIN AND POLYMYXIN B SULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Neomycin And Polymyxin B Sulfate patents expire, and when can generic versions of Neomycin And Polymyxin B Sulfate launch?
Neomycin And Polymyxin B Sulfate is a drug marketed by Watson Labs, Xgen Pharms, Bausch And Lomb, Padagis Us, Sciegen Pharms Inc, Alcon Pharms Ltd, Ipharm, Nordic Pharma, Amring Pharms, and Sandoz. and is included in twenty-one NDAs.
The generic ingredient in NEOMYCIN AND POLYMYXIN B SULFATE is bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEOMYCIN AND POLYMYXIN B SULFATE?
- What are the global sales for NEOMYCIN AND POLYMYXIN B SULFATE?
- What is Average Wholesale Price for NEOMYCIN AND POLYMYXIN B SULFATE?
Summary for NEOMYCIN AND POLYMYXIN B SULFATE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 21 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 3 |
DailyMed Link: | NEOMYCIN AND POLYMYXIN B SULFATE at DailyMed |